Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia
| Autor: | Izabella Lipinska, James E. Muller, Murray A. Mittleman, B W Walsh, G Bellotti, Otavio Gebara, Francine K. Welty, Geoffrey H. Tofler, F K Sacks |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Placebo-controlled study Hyperlipidemias Fibrinogen Placebo Drug Administration Schedule Double-Blind Method Internal medicine Fibrinolysis Hyperlipidemia medicine Humans Aged Cross-Over Studies Estradiol business.industry T-plasminogen activator Estrogen Replacement Therapy Middle Aged medicine.disease Crossover study Postmenopause Endocrinology Estrogen Tissue Plasminogen Activator Papers Female Progestins Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Heart (British Cardiac Society). 80(3) |
| ISSN: | 1355-6037 |
| Popis: | Objective—To study the effects of oestrogen replacement treatment on fibrinolytic potential in postmenopausal women. Design—Randomised, double blind, placebo controlled trial of oral 17β-oestradiol. Setting—Subjects were evaluated in the outpatient setting. Patients—Nineteen postmenopausal women with mild dyslipidaemia, aged 44 to 69 years (mean (SD) 55.7 (6.7)). Main outcome measures—Fibrinolytic activity (fibrin plate assay) and tissue plasminogen activator (t-PA) antigen were measured at baseline and after three, six, and nine weeks of each treatment. Results—After nine weeks of 2 mg oestradiol treatment, there was a significant increase in fibrinolytic potential compared with placebo, as indicated by an increase in fibrinolytic activity (mean (SEM), 80 (9) v 54 (5) mm2 of lysis in the fibrin plate, 2 mg v placebo, p = 0.002) and a decrease in t-PA antigen (5.8 (0.9) v 8.4 (1.2) ng/ml, 2 mg v placebo, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|